

I claim:

1. A method for inhibiting disorders characterized by elevated levels of basic fibroblast growth factor comprising administering to the individual having the disorder an effective amount of a curcuminoid to inhibit the basic fibroblast growth factor.
2. The method of claim 1 wherein the curcuminoid is administered topically.
3. The method of claim 1 wherein the disorder is bladder or cervical cancer.
4. A method for inhibiting skin disorders selected from the group consisting of lymphangiogenesis, hemangioma of childhood, Sturge-Weber syndrome, verruca vulgaris, neurofibromatosis, tuberous sclerosis, pyogenic granulomas, recessive dystrophic epidermolysis bullosa, venous ulcers, acne, rosacea, eczema, molluscum contagious, seborrheic keratosis, and actinic keratosis comprising administering to the individual in need of treatment thereof an angiogenesis inhibitor in an amount effective to inhibit angiogenesis.
5. The method of claim 4 wherein the angiogenesis inhibitor is applied topically.
6. The method of claim 5 wherein the angiogenesis inhibitor is selected from the group consisting of collagenase inhibitors, endostatin, angiostatin, fumagillin derivatives like TNP-470, 2,5-diaryltetrahydrofurans, aminophenylphosphonic acid compounds, 3-substituted oxindole derivatives, thalidomides, penicillamine and IL12.
7. The method of claim 4 wherein the angiogenesis inhibitor is a curcuminoid.
8. The method of claim 7 wherein the angiogenesis inhibitor is curcumin.
9. The method of claim 7 wherein the angiogenesis inhibitor is demethoxycurcumin.
10. A method to treat a disorder selected from the group consisting of angiosarcoma, hemangioendothelioma, basal cell carcinoma, squamous cell carcinoma, malignant melanoma and Kaposi's sarcoma, and psoriasis,

comprising administering to the individual in need of treatment an effective amount to inhibit angiogenesis of a curcuminoid.

11. The method of claim 10 wherein the angiogenesis inhibitor is curcumin.

12. The method of claim 10 wherein the angiogenesis inhibitor is demethoxycurcumin.

13. A pharmaceutical composition comprising a curcumin in combination with a pharmaceutically acceptable carrier for topical administration, wherein the curcumin is present in a dosage effective <sup>to penetrate the skin</sup> to treat a condition selected from the group consisting of lymphangiogenesis, hemangioma of childhood, Sturge-Weber syndrome, verruca vulgaris, neurofibromatosis, tuberous sclerosis, pyogenic granulomas, recessive dystrophic epidermolysis bullosa, venous ulcers, acne, rosacea, eczema, molluscum contagious, seborrheic keratosis, and actinic keratosis.

14. The composition of claim 13 wherein the carrier is an ointment or gel.

15. The composition of claim 14 as an ointment or hydrogel containing between one-half percent (0.5%) and five percent (5%) of the curcuminoid.

16. The composition of claim 13 wherein the carrier is a polymer formulation for implantation.